Hepatitis C virus prevention and care for drug injectors: the French approach

J-M Delile , Victor de Ledinghen (1) , Marie Jauffret-Roustide (2) , P Roux (3) , B Reiller , J Foucher (1) , D Dhumeaux

1 Hôpital Haut-Lévêque [CHU Bordeaux]
2 CERMES3 - UMR 8211 / U988 / UM 7 - CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société
3 SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale

After France removed hepatitis C treatment reimbursement restrictions on 25 May 2016, an expert report presented recommendations, which focused on vulnerable groups including people who inject drugs (PWID). This commentary presents the key points of the chapter with a particular focus on policy.

Domaines: Sciences de l'Homme et Société

J-M Delile, Victor de Ledinghen, Marie Jauffret-Roustide, P Roux, B Reiller, et al.. Hepatitis C virus prevention and care for drug injectors: the French approach. Hepatology, medicine and policy, 2018, 3 (1), pp.7. ⟨10.1186/s41124-018-0033-8⟩. ⟨hal-03480530⟩